health pharma news today obesity drugs glp-1 Drugmaker Eli Lilly announced that the FDA approved its daily pill, which will be marketed under the name Foundayo, to treat obesity. ABC News' Youri Benadjaoud reports. , The Wegovy pill is expected

Natarajan V, Ganju P, Ramkumar A, et al

Compared to M-CuP, D-CuP exhibited significantly higher proliferative activity at lower concentrations, which was more conducive to wound healing

The study included a survey with 1,955 useable observations including 495 people who were currently taking a GLP-1, 468 who had previously taken one, 492 people who were planning to take one, and 500 people who were neither taking one nor planning to take one

Intriguingly, this effect was observed exclusively in female mice, a result that was unexpected because females generally exhibit a more proficient defense against ROS than males [9]